
Leyden Laboratories B.V. has unveiled promising results from its study on intranasal antibody therapy, CR9114, which demonstrates broad-spectrum protection against influenza viruses, including A, B, C, and D strains. The research highlights the benefits of delivering antibodies directly to the…










